Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$91.03 USD

91.03
965,056

-1.02 (-1.11%)

Updated Aug 6, 2025 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Zacks Equity Research

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Zacks Equity Research

Boston Scientific (BSX) Gains From Acquisitions, New Launches

by Zacks Equity Research

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Zacks Equity Research

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

Zacks Equity Research

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

by Zacks Equity Research

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

Zacks Equity Research

Here's Why Investors Should Retain Henry Schein (HSIC) for Now

by Zacks Equity Research

Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.

Zacks Equity Research

Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay

by Zacks Equity Research

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

Zacks Equity Research

Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet

by Zacks Equity Research

Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.

Zacks Equity Research

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

by Zacks Equity Research

Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.

Indrajit Bandyopadhyay headshot

4 Medical Products Stocks to Capitalize on the Industry's Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

Zacks Equity Research

Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up

by Zacks Equity Research

Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.

Zacks Equity Research

What Makes Zimmer Biomet (ZBH) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Zacks Equity Research

Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 13.86% and 7.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ZBH or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. LMAT: Which Stock Is the Better Value Option?

Zacks Equity Research

Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.